Key Points
- Kyverna CTO Karen Marie Walker sold 23,998 shares on December 15 at an average price of $12.20 for roughly $292,776, cutting her stake by 51.46% to 22,636 shares, according to an SEC filing.
- KYTX traded at $6.79 on the most recent session with above-average volume (714,115 vs. a 599,762 average), a market cap of about $297 million, and a 12‑month range of $1.78 to $13.67.
- Analyst sentiment is mixed-to-positive: four buy ratings and one sell produce a consensus "Moderate Buy" with a consensus price target of $28.67, while several firms (including HC Wainwright, Wells Fargo and Morgan Stanley) have raised targets recently.
Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) CTO Karen Marie Walker sold 23,998 shares of the company's stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the completion of the transaction, the chief technology officer directly owned 22,636 shares of the company's stock, valued at approximately $276,159.20. This trade represents a 51.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Kyverna Therapeutics Price Performance
Shares of NASDAQ KYTX traded down $0.12 during trading hours on Thursday, reaching $6.79. The stock had a trading volume of 714,115 shares, compared to its average volume of 599,762. The company has a market cap of $297.36 million, a price-to-earnings ratio of -1.83 and a beta of 3.66. Kyverna Therapeutics, Inc. has a twelve month low of $1.78 and a twelve month high of $13.67. The business's fifty day moving average is $7.38 and its two-hundred day moving average is $5.13.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.12. Sell-side analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.
Institutional Trading of Kyverna Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in Kyverna Therapeutics during the 3rd quarter valued at about $28,000. Phoenix Wealth Advisors bought a new stake in shares of Kyverna Therapeutics during the second quarter worth approximately $32,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Kyverna Therapeutics during the second quarter worth approximately $37,000. Qube Research & Technologies Ltd acquired a new position in Kyverna Therapeutics in the second quarter valued at approximately $43,000. Finally, Ethic Inc. bought a new position in Kyverna Therapeutics in the second quarter valued at approximately $56,000. 18.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
KYTX has been the topic of several analyst reports. HC Wainwright upped their price objective on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a "buy" rating in a research note on Monday, October 27th. Wells Fargo & Company increased their price objective on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an "overweight" rating in a research note on Tuesday. Wall Street Zen raised shares of Kyverna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, December 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Kyverna Therapeutics in a research report on Monday. Finally, Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a research report on Monday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $28.67.
Read Our Latest Research Report on Kyverna Therapeutics
Kyverna Therapeutics Company Profile
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
